BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33482770)

  • 41. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neoadjuvant Chemotherapy for Breast Cancer: Moving Beyond Pathological Complete Response in the Molecular Age.
    Provenzano E
    Acta Med Acad; 2021 Apr; 50(1):88-109. PubMed ID: 34075766
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Axillary staging and management of cN + breast cancer patients treated with neoadjuvant chemotherapy: results of a survey among breast cancer surgeons in Spain.
    Munoz P; Corral S; Martínez-Regueira F; Paz A; Muñoz-Madero V; Mena A; Cabañas J; Rivas S
    Clin Transl Oncol; 2023 May; 25(5):1463-1471. PubMed ID: 36586064
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation.
    Newman EA; Sabel MS; Nees AV; Schott A; Diehl KM; Cimmino VM; Chang AE; Kleer C; Hayes DF; Newman LA
    Ann Surg Oncol; 2007 Oct; 14(10):2946-52. PubMed ID: 17514407
    [TBL] [Abstract][Full Text] [Related]  

  • 45. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
    Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study.
    Morency D; Dumitra S; Parvez E; Martel K; Basik M; Robidoux A; Poirier B; Holloway CMB; Gaboury L; Sideris L; Meterissian S; Boileau JF
    Ann Surg Oncol; 2019 Dec; 26(13):4337-4345. PubMed ID: 31605348
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlation between clinical nodal status and sentinel lymph node biopsy false negative rate after neoadjuvant chemotherapy.
    Takahashi M; Jinno H; Hayashida T; Sakata M; Asakura K; Kitagawa Y
    World J Surg; 2012 Dec; 36(12):2847-52. PubMed ID: 22806206
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sentinel lymph node biopsy using dye alone method is reliable and accurate even after neo-adjuvant chemotherapy in locally advanced breast cancer--a prospective study.
    Chintamani ; Tandon M; Mishra A; Agarwal U; Saxena S
    World J Surg Oncol; 2011 Feb; 9():19. PubMed ID: 21396137
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Accuracy and Limitations of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes.
    Aragon-Sanchez S; Oliver-Perez MR; Madariaga A; Tabuenca MJ; Martinez M; Galindo A; Arroyo ML; Gallego M; Blanco M; Ciruelos-Gil EM
    Breast J; 2022; 2022():1507881. PubMed ID: 36051467
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Validation sentinel lymph node biopsy study in cN0 axilla using low-cost dual dye technique: potential solution for resource poor settings.
    Chavda J; Mishra A; Silodia A; Yadav SK; Sharma DB; Sharma D; Khandare M
    Breast Cancer Res Treat; 2022 May; 193(1):105-110. PubMed ID: 35246773
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ultrasound-Guided Restaging and Localization of Axillary Lymph Nodes After Neoadjuvant Chemotherapy for Guidance of Axillary Surgery in Breast Cancer Patients: Experience with Activated Charcoal.
    Kim WH; Kim HJ; Jung JH; Park HY; Lee J; Kim WW; Park JY; Chae YS; Lee SJ
    Ann Surg Oncol; 2018 Feb; 25(2):494-500. PubMed ID: 29134374
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk of Positive Sentinel Lymph Node After Neoadjuvant Systemic Therapy in Clinically Node-Negative Breast Cancer: Implications for Postmastectomy Radiation Therapy and Immediate Breast Reconstruction.
    Samiei S; van Kaathoven BN; Boersma L; Granzier RWY; Siesling S; Engelen SME; de Munck L; van Kuijk SMJ; van der Hulst RRJW; Lobbes MBI; Smidt ML; van Nijnatten TJA
    Ann Surg Oncol; 2019 Nov; 26(12):3902-3909. PubMed ID: 31359276
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
    Kuerer HM; Sahin AA; Hunt KK; Newman LA; Breslin TM; Ames FC; Ross MI; Buzdar AU; Hortobagyi GN; Singletary SE
    Ann Surg; 1999 Jul; 230(1):72-8. PubMed ID: 10400039
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
    Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of axillary response by monitoring with ultrasound and MRI during and after neoadjuvant chemotherapy in breast cancer patients.
    Eun NL; Son EJ; Gweon HM; Kim JA; Youk JH
    Eur Radiol; 2020 Mar; 30(3):1460-1469. PubMed ID: 31802216
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
    Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
    Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Axillary pathologic response after neoadjuvant chemotherapy in locally advanced breast cancer with axillary involvement].
    Jiménez-Ballvé A; Serrano-Palacio A; García-Sáenz JA; Ortega Candil A; Salsidua-Arroyo O; Román-Santamaría JM; Pelayo Alarcón A; Fuentes Ferrer ME; Carreras-Delgado JL
    Rev Esp Med Nucl Imagen Mol; 2015; 34(4):230-5. PubMed ID: 25743035
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
    Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
    Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Axillary staging in the neoadjuvant setting.
    Chung A; Giuliano A
    Ann Surg Oncol; 2010 Sep; 17(9):2401-10. PubMed ID: 20229221
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diagnostic accuracy of de-escalated surgical procedure in axilla for node-positive breast cancer patients treated with neoadjuvant systemic therapy: A systematic review and meta-analysis.
    Song YX; Xu Z; Liang MX; Liu Z; Hou JC; Chen X; Xu D; Fei YJ; Tang JH
    Cancer Med; 2022 Nov; 11(22):4085-4103. PubMed ID: 35502768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.